TY - JOUR T1 - Protecting people with multiple sclerosis through vaccination JF - Practical Neurology JO - Pract Neurol SP - 435 LP - 445 DO - 10.1136/practneurol-2020-002527 VL - 20 IS - 6 AU - Saúl Reyes AU - Mary Ramsay AU - Shamez Ladhani AU - Gayatri Amirthalingam AU - Neena Singh AU - Carlos Cores AU - joela Mathews AU - Jonathan Lambourne AU - Monica Marta AU - Benjamin Turner AU - Sharmilee Gnanapavan AU - Ruth Dobson AU - Klaus Schmierer AU - G Giovannoni Y1 - 2020/12/01 UR - http://pn.bmj.com/content/20/6/435.1.abstract N2 - Vaccination is one of the most effective and cost-efficient methods for protecting people with multiple sclerosis (MS) from infections. However, use of vaccines has often been problematic because of misguided concerns that they may exacerbate the disease and/or that some disease-modifying therapies may influence the immune response to immunisations and/or their safety. People with MS risk higher morbidity and mortality from vaccine-preventable infections. It is, therefore, important to address any patient’s reluctance to accept vaccination and to provide clear guidance for clinicians on which vaccinations to consider proactively. We have reviewed the current literature and provide recommendations regarding vaccines in adults with MS, including specific advice regarding vaccination safety in patients receiving—or going to receive—disease-modifying therapies, vaccination during pregnancy, pretravel counselling and patient education. ER -